Monitor this situation.
Unsubscribe anytime.
[SITUATION] · [ACTIVE] · [HEALTH]
2 clusters · 7 sources · 7 days · First seen · Last updated
Mayo Clinic pancreatic cancer vaccine clinical trial
Overview
Researchers at Mayo Clinic have reported promising results from a phase 2 clinical trial of an investigational, ‘off the shelf’ vaccine designed to target KRAS mutations in pancreatic ductal adenocarcinoma. The study, published in Nature Medicine, found that the vaccine, known as camupepimut, triggered an immune response in 98.9% of the 144 evaluated patients.
The treatment works by delivering fragments of seven common KRAS mutations to the lymph nodes to stimulate T-cell activity against cancer cells. While an exploratory analysis suggested that stronger immune responses may correlate with longer disease-free survival, researchers noted that the trial has not yet conclusively proven that the vaccine reduces cancer recurrence or increases overall survival rates. These findings are expected to inform the design of upcoming phase 3 clinical trials.
Entities
Timeline
-
[HEALTH] 3 sourcesMayo Clinic experimental pancreatic cancer vaccine shows immune response
A phase 2 clinical trial of the experimental vaccine camupepimut showed an immune response in 98.9% of patients with KRAS-mutated pancreatic cancer.
-
[HEALTH] 3 sourcesMayo Clinic vaccine shows promise in pancreatic cancer trial
A Mayo Clinic phase 2 trial shows an investigational ‘off the shelf’ vaccine can trigger immune responses against KRAS mutations in pancreatic cancer patients.
Sources
br.paipee.com · chacoprensa.com · es.gizmodo.com · news-medical.net · newswise.com · southfloridahospitalnews.com · tveuropa.pt